M
Mycophenolate Mofetil
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Standard Drug List
Active ingredient: Mycophenolate
General information
Subsidy Information and Financing Scheme
[SDL] Mycophenolate Mofetil Capsule 250 mg
[SDL] Mycophenolate Mofetil Infusion 500 mg
[SDL] Mycophenolate Mofetil Tablet 500 mg
[SDL] Mycophenolate Mofetil Oral Suspension 1,000 mg/5 mL
Drug Guidance for Subsidy
01/09/2020 Mycophenolate mofetil for immunosuppression
The MOH Drug Advisory Committee has recommended to:
Reclassify mycophenolate mofetil 250 mg capsule and 500 mg tablet from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
List mycophenolate mofetil 500 mg powder for solution for infusion on the SDL
in view of favourable cost effectiveness compared to other immunosuppressants at the prices proposed by the manufacturer.
Subsidy status
[R] SDL subsidy will apply for induction and maintenance treatment of active lupus nephritis and for all registered indications of mycophenolate mofetil in Singapore:
Prophylaxis of acute organ rejection and treatment of refractory organ rejection in patients receiving allogeneic renal transplants,
Prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants, and
Prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 250 mg |
|
Infusion 500 mg |
|
Tablet 500 mg |
|
Oral Suspension 1,000 mg/5 mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
Intravenous
* Clinical information is available for this product.